Latest news

• Daily Brief: Europe changes mind on Puma drug, Pfizer's Healthcare Hub, AbbVie and Calico add $1bn to anti-ageing quest

  The EMA's Committee for Medicinal Products for Human Use (CHMP) is set to approve the use of Puma Biotechnology’s neratinib for the extended adjuvant treatment of early stage HER2

• Pfizer’s leukaemia drug Mylotarg backed for use in EU

  There was worse news for Puma Biotechnology - which has its application to market Nerlyx (neratinib) for breast cancer turned down - and also Pfizer whose application to extend the indications of Sutent

• Roche trumpets APHINITY data, but did it hit the mark?

  The results of the APHINITY trial could present an opportunity to US biotech Puma, which won a positive recommendation from an FDA advisory committee for its neratinib candidate in post-surgery ... In trials, neratinib achieved a 33% reduction in the

• FDA panel backs Puma's breast cancer drug, with reservations

  Side effects concerns could see medicines limited. US biotech Puma took a step closer to approval of its breast cancer therapy neratinib after an FDA advisory committee voted in favour of ... A number of analysts have suggested neratinib may be approved

• Oncology bias in pharma deals

  Pfizer has licensed the worldwide commercial rights of Neratinib, a phase II pan-HER inhibitor (potent irreversible tyrosine kinase inhibitor) in the neoadjuvant, adjuvant and advanced settings in HER2/ErbB2 positive ... 2 ##. Pfizer/Puma Biotechnology ##